This report provides an in-depth analysis of the product pipeline and developer companies, highlighting the current treatment practices, emerging drugs, and market share of the individual therapies. In addition to other elements, the study includes detailed assessment of the current market landscape, providing information about the product

This report provides an in-depth analysis of the product pipeline and developer companies, highlighting the current treatment practices, emerging drugs, and market share of the individual therapies. In addition to other elements, the study includes detailed assessment of the current market landscape, providing information about the product

This report provides an in-depth analysis of the product pipeline and developer companies, highlighting the current treatment practices, emerging drugs, and market share of the individual therapies. In addition to other elements, the study includes detailed assessment of the current market landscape, providing information about the product

This report provides an in-depth analysis of the product pipeline and developer companies, highlighting the current treatment practices, emerging drugs, and market share of the individual therapies. In addition to other elements, the study includes detailed assessment of the current market landscape, providing information about the product

This report provides an in-depth analysis of the product pipeline and developer companies, highlighting the current treatment practices, emerging drugs, and market share of the individual therapies. In addition to other elements, the study includes detailed assessment of the current market landscape, providing information about the product

The global DNA damage response market is estimated to grow from USD 390 million in 2026 to reach USD 1,071 million by 2030 representing a higher CAGR of 28.7% during the forecast period. Although majority of the drug candidates for molecular targets (other than PARP) are in the preclinical / initial clinical stages, drug developers are optimistic regarding the therapeutic potential of this emerging class of drugs. Gradually, a substantial body of evidence, validating the efficacy of drugging the...

The pharma contract research organization (CRO) services market is estimated to be worth $25 billion in 2021 and is expected to grow at CAGR of 10% during the forecast period. Small molecule drugs account for nearly 90% of the contemporary therapeutics pipeline. In 2020, the US FDA

This report provides an in-depth analysis of the product pipeline and developer companies, highlighting the current treatment practices, emerging drugs, and market share of the individual therapies. In addition to other elements, the study includes detailed assessment of the current market landscape, providing information about the product

This report provides an in-depth analysis of the product pipeline and developer companies, highlighting the current treatment practices, emerging drugs, and market share of the individual therapies. In addition to other elements, the study includes detailed assessment of the current market landscape, providing information about the product

The "Hydrogen Energy Storage Market: Global Opportunity and Trend Analysis, 2021-2031” report features an extensive study of the current market landscape of stakeholders engaged in this emerging industry.

This report provides an in-depth analysis of the product pipeline and developer companies, highlighting the current treatment practices, emerging drugs, and market share of the individual therapies. In addition to other elements, the study includes detailed assessment of the current market landscape, providing information about the product

The global lipid CMO market size, valued at USD 4.41 billion in 2025, is projected to reach USD 4.59 billion in 2026 and USD 5.64 billion by 2030, with a CAGR of 5.3% during the forecast period 2026 to 2030. Around 90% of the drug candidates in the current development pipeline and close to 40% of marketed pharmacological products, have been associated with concerns related to solubility and / or permeability. As a result lipid nanoparticles and the use of various lipid-based excipients (which i...

The Middle East renewable energy market reached USD 58.5 billion in 2026 and is projected to grow to USD 235.0 billion by 2040, registering a CAGR of 10.4% over the forecast period 2026 to 2040, driven by utility-scale solar procurement, grid storage, and national diversification programs.

The novel T-cell immunotherapy market is estimated to be worth $25 million in 2021 and is expected to grow at CAGR of 76% during the forecast period. At present, the novel T-cell immunotherapies pipeline features over 200 product candidates and is anticipated to grow in the foreseen future. Further, more than 35 such therapies, including Tab-cel

The glycan analysis market is estimated to be worth $456 million in 2021 and is expected to grow at CAGR of 20.8% during the forecast period. Recombinant glycoprotein therapeutics, which include antibody-based interventions, have emerged as one of the fastest growing classes of pharmacologically active molecules. Till date, over 67% of biologics and 80% of biosimilars approved by the FDA, feature some form of glycosylation. In fact, the pipeline of such interventions is also growing at a commend...

Adalimumab was the first fully humanized, monoclonal antibody drug to be approved by the US FDA in 2002. The product was subsequently launched in 2003, and initially only indicated for the treatment of rheumatoid arthritis. In the succeeding years since its launch, HUMIRA® gradually approved for the treatment of psoriatic arthritis (2005), ankylosing spondylitis (2006), Crohn’s disease (2007), plaque psoriasis (2008), ulcerative colitis (2012), hidradenitis suppurativa (2015), among a few oth...

The global drug discovery platforms market, valued at USD 198 million in 2025, is projected to reach USD 225 million in 2026 and USD 375 million by 2030, with a 13.6% CAGR during the forecast period, 2026 to 2030. In modern medical research, display libraries have been successfully employed for the generation of various novel therapeutics and offer certain advantages over conventional drug screening methods, including (but not limited to) the ability to facilitate large-scale, high throughput sc...